FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595809497> ?p ?o ?g. }

• W2595809497 endingPage "51858" @default.
• W2595809497 startingPage "51848" @default.
• W2595809497 abstract "// Ming Liu 1,2,* , Zhongtang Wang 2,* , Tao Zhou 2 , Antang Zhou 3 , Qian Zhao 2 , Hongsheng Li 2 , Hongfu Sun 2 , Wei Huang 2 and BaoSheng Li 2,4 1 School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China 2 Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China 3 Department of General Surgery, Yanggu People’s Hospital, Liaocheng, Shandong, P.R. China 4 Engineering Research Center for Medical Imaging and Radiation Therapy of Shandong Province, Jinan, Shandong, P.R. China * These authors have contributed equally to this study and should be considered as co-first authors Correspondence to: BaoSheng Li, email: // Keywords : non-small cell lung cancer, chemoradiotherapy, lung V20, Individual isotoxic dose escalation, advanced radiotherapy technologies Received : September 30, 2016 Accepted : March 09, 2017 Published : March 16, 2017 Abstract Under the assumption that the highest therapeutic ratio could be achieved by increasing the total tumor dose (TTD) to the limits of normal tissues, the phase I trial was conducted in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy, to determine the feasibility and effects of individual isotoxic radiation dose escalation based on bilateral lung V20 and advanced technologies. Consecutive eligible patients were assigned to cohorts of eight. V20 of each cohort was increased from 27% to 30%, 33%, 35%, 37%, and so on. The criterion for cessation of dose escalation was defined as ≥ 2 patients in each cohort experienced dose limiting toxicity. Isotoxic dose escalation was based on V20, functional imaging was used to improve the accuracy of radiotherapy. To test the power of escalation dose, patients with TTD over 66 Gy were assigned to the higher dose group (HD), while the others to the standard dose one (SD). In result, the recommended value of V20 was 35%. For all patients, follow-up ranged from 1 to 112 months, median overall and progression free survivals were 25.0 and 13.0 months, respectively. The 1-, 3-, 5- and 8-year overall survival (OS) rates were 72.5%, 22.5%, 17.5%, and 10.0%, respectively. Especially, the OS and local recurrence-free survival of patients in HD group were significantly longer than those in SD one ( P =0.035, P=0.007, respectively) without increasing severe toxicity. Thus, individual isotoxic dose escalation based on V20 with advanced technologies was feasible and effective." @default.
• W2595809497 created "2017-03-23" @default.
• W2595809497 creator A5001559303 @default.
• W2595809497 creator A5019056174 @default.
• W2595809497 creator A5024916524 @default.
• W2595809497 creator A5026051264 @default.
• W2595809497 creator A5029470409 @default.
• W2595809497 creator A5049631568 @default.
• W2595809497 creator A5065073978 @default.
• W2595809497 creator A5066993441 @default.
• W2595809497 creator A5089117918 @default.
• W2595809497 date "2017-03-16" @default.
• W2595809497 modified "2023-10-17" @default.
• W2595809497 title "Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up" @default.
• W2595809497 cites W1963989756 @default.
• W2595809497 cites W1965175564 @default.
• W2595809497 cites W1967593563 @default.
• W2595809497 cites W1968899146 @default.
• W2595809497 cites W1974498402 @default.
• W2595809497 cites W1978788134 @default.
• W2595809497 cites W1983372287 @default.
• W2595809497 cites W1991345460 @default.
• W2595809497 cites W1996128860 @default.
• W2595809497 cites W1999583781 @default.
• W2595809497 cites W2002913510 @default.
• W2595809497 cites W2003456733 @default.
• W2595809497 cites W2004872627 @default.
• W2595809497 cites W2008631325 @default.
• W2595809497 cites W2026788229 @default.
• W2595809497 cites W2032100009 @default.
• W2595809497 cites W2032698262 @default.
• W2595809497 cites W2033699280 @default.
• W2595809497 cites W2039108600 @default.
• W2595809497 cites W2048920475 @default.
• W2595809497 cites W2051767374 @default.
• W2595809497 cites W2053688176 @default.
• W2595809497 cites W2056514179 @default.
• W2595809497 cites W2057468569 @default.
• W2595809497 cites W2059589551 @default.
• W2595809497 cites W2092980747 @default.
• W2595809497 cites W2093745890 @default.
• W2595809497 cites W2111033515 @default.
• W2595809497 cites W2111162768 @default.
• W2595809497 cites W2113775428 @default.
• W2595809497 cites W2117385821 @default.
• W2595809497 cites W2122999279 @default.
• W2595809497 cites W2124621771 @default.
• W2595809497 cites W2129144587 @default.
• W2595809497 cites W2137494898 @default.
• W2595809497 cites W2137667247 @default.
• W2595809497 cites W2138705226 @default.
• W2595809497 cites W2139248078 @default.
• W2595809497 cites W2144475774 @default.
• W2595809497 cites W2155422011 @default.
• W2595809497 cites W2160797118 @default.
• W2595809497 cites W2196797460 @default.
• W2595809497 cites W2226077283 @default.
• W2595809497 doi "https://doi.org/10.18632/oncotarget.16288" @default.
• W2595809497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5584295" @default.
• W2595809497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28881694" @default.
• W2595809497 hasPublicationYear "2017" @default.
• W2595809497 type Work @default.
• W2595809497 sameAs 2595809497 @default.
• W2595809497 citedByCount "8" @default.
• W2595809497 countsByYear W25958094972019 @default.
• W2595809497 countsByYear W25958094972020 @default.
• W2595809497 countsByYear W25958094972021 @default.
• W2595809497 countsByYear W25958094972022 @default.
• W2595809497 countsByYear W25958094972023 @default.
• W2595809497 crossrefType "journal-article" @default.
• W2595809497 hasAuthorship W2595809497A5001559303 @default.
• W2595809497 hasAuthorship W2595809497A5019056174 @default.
• W2595809497 hasAuthorship W2595809497A5024916524 @default.
• W2595809497 hasAuthorship W2595809497A5026051264 @default.
• W2595809497 hasAuthorship W2595809497A5029470409 @default.
• W2595809497 hasAuthorship W2595809497A5049631568 @default.
• W2595809497 hasAuthorship W2595809497A5065073978 @default.
• W2595809497 hasAuthorship W2595809497A5066993441 @default.
• W2595809497 hasAuthorship W2595809497A5089117918 @default.
• W2595809497 hasBestOaLocation W25958094971 @default.
• W2595809497 hasConcept C126322002 @default.
• W2595809497 hasConcept C143998085 @default.
• W2595809497 hasConcept C146357865 @default.
• W2595809497 hasConcept C151730666 @default.
• W2595809497 hasConcept C2776256026 @default.
• W2595809497 hasConcept C2778424827 @default.
• W2595809497 hasConcept C2989005 @default.
• W2595809497 hasConcept C509974204 @default.
• W2595809497 hasConcept C71924100 @default.
• W2595809497 hasConcept C86803240 @default.
• W2595809497 hasConceptScore W2595809497C126322002 @default.
• W2595809497 hasConceptScore W2595809497C143998085 @default.
• W2595809497 hasConceptScore W2595809497C146357865 @default.
• W2595809497 hasConceptScore W2595809497C151730666 @default.
• W2595809497 hasConceptScore W2595809497C2776256026 @default.
• W2595809497 hasConceptScore W2595809497C2778424827 @default.
• W2595809497 hasConceptScore W2595809497C2989005 @default.
• W2595809497 hasConceptScore W2595809497C509974204 @default.

• next